ChemicalBook > CAS DataBase List > Immunoglobulin G4,anti-(human integrin R4) (human-mouse monoclonal AN100226 c4-chain),disulfide with human-mouse monoclonal AN100226 light chain,dimer

Immunoglobulin G4,anti-(human integrin R4) (human-mouse monoclonal AN100226 c4-chain),disulfide with human-mouse monoclonal AN100226 light chain,dimer

Product Name
Immunoglobulin G4,anti-(human integrin R4) (human-mouse monoclonal AN100226 c4-chain),disulfide with human-mouse monoclonal AN100226 light chain,dimer
CAS No.
189261-10-7
Chemical Name
Immunoglobulin G4,anti-(human integrin R4) (human-mouse monoclonal AN100226 c4-chain),disulfide with human-mouse monoclonal AN100226 light chain,dimer
Synonyms
Natalizumab-Tysabri;Research Grade Natalizumab(DHC98801);inhibit,Inhibitor,Natalizumab,Integrin;Immunoglobulin G4,anti-(human integrin R4) (human-mouse monoclonal AN100226 c4-chain),disulfide with human-mouse monoclonal AN100226 light chain,dimer
CBNumber
CB03204652
Molecular Formula
C40H55N7O11S
Formula Weight
841.97
MOL File
189261-10-7.mol
More
Less

Immunoglobulin G4,anti-(human integrin R4) (human-mouse monoclonal AN100226 c4-chain),disulfide with human-mouse monoclonal AN100226 light chain,dimer Property

storage temp. 
Store at 4°C, do not freeze
form 
Liquid
color 
Colorless to light yellow
More
Less

Safety

Hazardous Substances Data
189261-10-7(Hazardous Substances Data)
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

American Custom Chemicals Corporation
Product number
ATB0023422
Product name
NATALIZUMAB
Purity
95.00%
Packaging
5MG
Price
$497.53
Updated
2021/12/16
ChemScene
Product number
CS-0031133
Product name
Natalizumab
Packaging
10mg
Price
$825
Updated
2021/12/16
ChemScene
Product number
CS-0031133
Product name
Natalizumab
Packaging
25mg
Price
$1200
Updated
2021/12/16
DC Chemicals
Product number
013332
Product name
Natalizumab
Packaging
003
Price
$1800
Updated
2021/12/16
More
Less

Immunoglobulin G4,anti-(human integrin R4) (human-mouse monoclonal AN100226 c4-chain),disulfide with human-mouse monoclonal AN100226 light chain,dimer Chemical Properties,Usage,Production

Description

The a4 family of integrins expressed on the surface of leukocytes are involved in cell adhesion processes. The α4 integrin can pair with either of two b subunits to generate a heterodimeric cell surface receptor known as α4β1 (VLA4) or α4β7. Ligands for VLA4 include vascular cell adhesion molecule-1 (VCAM-1), which is expressed on activated vascular endothelium, while α4β7 interacts predominantly with mucosal addressin cell adhesion molecule-1 (MadCAM-1) existing on vascular endothelial cells of the gastrointestinal tract. By virtue of this α4–mediated interaction between leukocytes and vascular endothelial cells that leads to trans-endothelial infiltration of various leukocytes (lymphocytes, monocytes, T-cells, etc.) at the site of inflammation, interference with the adhesion of the α4 integrin has been deemed a viable approach for disrupting the inflammatory cascade. As an antibody that binds to the α4 integrin subunit, natalizumab has been developed and launched for the treatment of multiple sclerosis, a chronic inflammatory disorder of the central nervous system. It is also being developed for other chronic inflammatory diseases, such as, Crohn’s disease, rheumatoid arthritis, and irritable bowel syndrome (IBS). Natalizumab is a recombinant humanized monoclonal antibody produced in murine myeloma cells. It contains human framework regions and the complementarity-determining regions of an antibody that is targeted to the α4 integrin. For the treatment of irritable bowel diseases (Crohn’s disease, ulcerative colitis, and IBS), the target is the α4β7 glycoprotein while efficacy in treating MS is attributed to binding to the α4 subunit of α4β1. For MS, the binding of natalizumab prevents docking of VCAM-1 to its receptor on leukocytes, thereby, effectively inhibiting leukocyte trafficking across the blood brain-barrier (BBB). A reduction in migration across the BBB translates into a reduction in lesions and relapses. In a two-year, placebo-controlled, double blind phase III study, a oncemonthly, 300 mg i.v. infusion of natalizumab reduced relapses by 66% compared to placebo. All of the secondary endpoints, such as, the number of new or newly enlarging T2-hyperintense lesions, the number of gadolinium-enhancing lesions, and the proportion of relapse-free patients, were all met. Regarding side effects, headache, fatigue, and arthralgia were reported in 5% of natalizumab patients, 2% more common than observed with placebo. Serious hypersensitivity-like reactions were experienced in 1% of the natalizumab group. In these cases, adverse effects usually developed within two hours of the onset of the infusion. The symptoms included urticaria, fever, rash, rigors, dizziness, pruritus, nausea, flushing, dyspnea, hypotension, and chest pain. Antibodies to natalizumab are believed to be responsible, and any patient experiencing hypersensitivity should discontinue further treatment. Since adequate studies have not been performed in the pregnant, pediatric, and elderly, natalizumab is currently contraindicated in these patient populations. In addition, this drug should not be taken concurrent with medications that suppress the immune system, such as, corticosteroids; the combination increases the risk for serious infections. With a dose of 300 mg to MS patients, the long half-life of 11±4 days results in a once-a-month trip to the physician for the one-hour infusion. Natalizumab is cleared at a rate of 16 mL/h with a Cmax of 98 μg/ mL and a mean steady-state concentration of approximately 30 μg/mL.

Originator

Elan (UK)

brand name

Tysabri

Immunoglobulin G4,anti-(human integrin R4) (human-mouse monoclonal AN100226 c4-chain),disulfide with human-mouse monoclonal AN100226 light chain,dimer Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Immunoglobulin G4,anti-(human integrin R4) (human-mouse monoclonal AN100226 c4-chain),disulfide with human-mouse monoclonal AN100226 light chain,dimer Suppliers

Nanjing Sunlida Biological Technology Co., Ltd.
Tel
025-57798810
Fax
025-57019371
Email
sales@sunlidabio.com
Country
China
ProdList
3239
Advantage
55
Taizhou KEDE Chemical Co., Ltd
Tel
0576-84613060 13093829633
Fax
0576-84613060
Email
sales@kedechemical.com
Country
China
ProdList
298
Advantage
60
Shanghai EFE Biological Technology Co., Ltd.
Tel
021-65675885 18964387627
Fax
021-65675885
Email
info@efebio.com
Country
China
ProdList
9806
Advantage
58
ShangHai Biochempartner Co.,Ltd
Tel
177-54423994 17754423994
Fax
QQ:2853530913
Email
2853530910@QQ.com
Country
China
ProdList
8011
Advantage
62
Beijing Solarbio Science & Tecnology Co., Ltd.
Tel
010-50973130 4009686088
Email
3193328036@qq.com
Country
China
ProdList
29785
Advantage
68
Hefei Hirisun Pharmatech Co., Ltd.
Tel
+86-0551-62678551 +86-15056975894
Fax
0551-62678551
Email
sales@hirisunpharm.com
Country
China
ProdList
181
Advantage
55
Chemleader Biomedical Co., Limited.
Tel
021-58180488
Fax
021-58180499
Email
sales@Medchemleader.com
Country
China
ProdList
1005
Advantage
58
Fan De(Beijing) Biotechnology Co., Ltd.
Tel
15911056312
Email
liming@bio-fount.com
Country
China
ProdList
9729
Advantage
58
Hefei Hirisun Pharmatech Co., Ltd
Tel
+8615056975894
Fax
86-0551-62678551
Email
shawn@hirisunpharm.com
Country
CHINA
ProdList
9911
Advantage
58
Baoji Guokang Healthchem co.,ltd
Tel
+8615604608665 15604608665
Email
dominicguo@gk-bio.com
Country
CHINA
ProdList
9414
Advantage
58
DC Chemicals
Tel
021-58447131 13564518121
Email
sales@dcchemicals.com
Country
China
ProdList
9409
Advantage
58
Guangzhou Hongyuan Chemical Co.,Ltd
Tel
15817493340
Email
981810490@qq.com
Country
China
ProdList
1566
Advantage
58
Wuhan Chemstan Biotechnology Co., Ltd.
Tel
027-65317797 15926423062
Fax
QQ:422450190
Email
422450190@qq.com
Country
China
ProdList
10359
Advantage
58
Hubei Zhongshan Medical Technology Co., Ltd
Tel
027-61907345 13397111514
Fax
3443707954
Email
w13397111514@163.com
Country
China
ProdList
1010
Advantage
58
Shanghai Minkai Biological Technology Co., Ltd
Tel
021-021-52919136 17315815539
Email
2804155403@qq.com
Country
China
ProdList
205
Advantage
58
Jiangxi ravel Biotechnology Co.,Ltd
Tel
400-880-2824 18107960669
Fax
18140514863
Email
79046690@qq.com
Country
China
ProdList
1267
Advantage
58
Beijing Jin Ming Biotechnology Co., Ltd.
Tel
010-60605840 15801484223;
Email
psaitong@jm-bio.com
Country
China
ProdList
29774
Advantage
58
SUZHOU MAYSIXTH TRADING CO.LTD
Tel
17715515539
Email
zhangxin@maysixth.cn
Country
China
ProdList
58
Advantage
58
Hubei Kele Fine Chemical Co., Ltd
Tel
027-59101668 19945030958
Fax
027-59101668
Email
2881924765@qq.com
Country
China
ProdList
8140
Advantage
58
Hubei wei shi reagent group ltd., company
Tel
027-59102966 18717199209
Fax
027-59379337
Email
2853877583@qq.com
Country
China
ProdList
3522
Advantage
58
Bide Pharmatech Ltd.
Tel
400-1647117 13681763483
Email
product02@bidepharm.com
Country
China
ProdList
62163
Advantage
58
Jiangxi ravel Biotechnology Co.,Ltd
Tel
400-880-2824 15608648206
Email
1987516016@qq.com
Country
China
ProdList
2811
Advantage
58
Wuhan Yingnuo Pharmaceutical Technology Co., Ltd.
Tel
+86-027-59232304 15387063101
Email
2881924050@qq.com
Country
China
ProdList
9951
Advantage
58
TargetMol Chemicals Inc.
Tel
4008200310
Email
marketing@tsbiochem.com
Country
China
ProdList
24647
Advantage
58
Hubei wei shi reagent group ltd., company
Tel
027-59105166 13125137732
Email
2853863890@qq.com
Country
China
ProdList
2981
Advantage
58
Hubei Wanye Zhongcheng Chemical Reagent Co., Ltd.
Tel
18671296875 18671296875
Email
1205035102@qq.com
Country
China
ProdList
4303
Advantage
58
Biolab Reagents
Tel
027-65279366 18162686757
Email
products@biolabreagent.com
Country
China
ProdList
9818
Advantage
58
Wuhan Jingkangen Biomedical Technology Co., Ltd
Tel
13720134139 13720134139
Email
orders@jknbiochem.com
Country
China
ProdList
5797
Advantage
58
Wuhan Acumen Bio-Technology Co.,ltd
Tel
027-027-16602739303 16602739303
Email
673003916@qq.com
Country
China
ProdList
3059
Advantage
58
Nanjing Shizhou Biology Technology Co.,Ltd
Tel
025-85560043 15850508050
Fax
025-85563444
Email
cindy.huang@synzest.com
Country
China
ProdList
12005
Advantage
58
Shanghai jerryxing Biomedical Technology Co., Ltd
Tel
17721492509
Email
643638326@qq.com
Country
China
ProdList
5345
Advantage
58
Changsha Fuzhen Biotechnology Co.,LTD
Tel
13823398779 18670069958
Email
3062105966@qq.com
Country
China
ProdList
3262
Advantage
58
Hubei wei shi reagent group ltd., company
Tel
027-59102966 18717199209
Email
2853877583@QQ.com
Country
China
ProdList
7850
Advantage
58
Hubei wei shi reagent group ltd., company
Tel
027-02759101766 13125137661
Email
2853877621@qq.com
Country
China
ProdList
5421
Advantage
58
RD International Technology Co., Limited
Tel
18024082417
Email
market@ubiochem.com
Country
China
ProdList
9272
Advantage
58
Minglong (Xianning) Pharmaceutical Co., LTD
Tel
155-7155-6913 15571556913
Email
354024111@qq.com
Country
China
ProdList
2596
Advantage
58
Wanxin Biotechnology (Jiaxing) Co., LTD
Tel
0573-83568680 18057391398
Email
3956524501@qq.com
Country
China
ProdList
1442
Advantage
58
SHANGHAI KEAN TECHNOLOGY CO., LTD.
Tel
+8613817748580
Fax
021-50175322
Email
cooperation@kean-chem.com
Country
China
ProdList
40066
Advantage
58
Shanghai Acmec Biochemical Technology Co., Ltd.
Tel
+undefined18621343501
Email
product@acmec-e.com
Country
China
ProdList
33338
Advantage
58
Shanghai Minbiotech Co., Ltd.
Tel
+8617315815539
Email
sales@minbiotech.com
Country
CHINA
ProdList
129
Advantage
58

189261-10-7, Immunoglobulin G4,anti-(human integrin R4) (human-mouse monoclonal AN100226 c4-chain),disulfide with human-mouse monoclonal AN100226 light chain,dimerRelated Search:


  • Immunoglobulin G4,anti-(human integrin R4) (human-mouse monoclonal AN100226 c4-chain),disulfide with human-mouse monoclonal AN100226 light chain,dimer
  • Natalizumab-Tysabri
  • Research Grade Natalizumab(DHC98801)
  • inhibit,Inhibitor,Natalizumab,Integrin
  • 189261-10-7